Rezolute Inc. (RZLT)

[Whalatane]

RMB. The P2 DME trial is probably a long shot to show clinically relevant improvement . Dew ( biotech values ) was of the opinion that there was a narrow therapeutic window ( which means I think that at high enough dose to see clinically relevant benefit , you'll probably see a lot more side effects .)
I'm hopefully tho because of the involvement of this KOL ...Robert B Bhisikul MD ..UCSF Prof of Ophthalmology and Retinal Specialist .
UCSF are cutting edge ...I was in a Cardiovascular trial their years ago

“We’re in need of new treatments in the clinical care of patients with diabetic eye diseases,” said Robert B. Bhisitkul, M.D., Ph.D., Professor of Ophthalmology and Retinal Specialist at the University of California San Francisco School of Medicine’s Department of Ophthalmology, and member of Rezolute’s Scientific Advisory Board.
“Pioneering research has strongly implicated the kallikrein-kinin system in the development of diabetic retinopathy and macular edema.
A novel plasma kallikrein inhibitor has potential to give patients with diabetic macular edema an alternative therapeutic option.
Oral delivery would provide the possibility of earlier treatment intervention and enable a patient-controlled regimen with advantages in comfort, convenience, and continuous drug levels in the retinal microvasculature.
I look forward to the continued development of RZ402 for patients at risk of losing their sight from DME.”

Current treatment is via an eye injection which is often delayed until sight has significantly deteriorated. A drug eluting insert is in development ( or maybe in use ) .
OCUL ( I have a small position ) also working in the field.

RZLT hopes drug will at least slow progression and may also be a supplement to injections and inserts.

Insider buying recently
Kiwi